Supernus Pharmaceuticals, Inc. announced Intangible asset impairment charges for the quarter ended December 31, 2023. For the quarter, the company reported Intangible asset impairment charges of $20,189,000.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
25.68 USD | -1.93% | -7.92% | -11.16% |
May. 23 | Supernus Pharmaceuticals Reports 'Clinical Utility' From Epilepsy Treatment Study | MT |
May. 23 | Transcript : Supernus Pharmaceuticals, Inc. - Special Call |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.16% | 1.44B | |
+19.29% | 80.29B | |
+15.04% | 9.2B | |
-18.33% | 4.67B | |
+43.39% | 4.49B | |
+13.95% | 4.27B | |
+10.46% | 2.25B | |
-28.40% | 2.13B | |
+15.93% | 2.1B | |
-43.17% | 1.78B |
- Stock Market
- Equities
- SUPN Stock
- News Supernus Pharmaceuticals, Inc.
- Supernus Pharmaceuticals, Inc. Announces Intangible Asset Impairment Charges for the Quarter Ended December 31, 2023